With an expiration date still more than a year away, here's what the latest details reveal.

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.

News and commentary from the psychiatry world ...

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...

The FDA approved external trigeminal nerve stimulation (TNS) in 2019 as the first non-drug device for treating ADHD, researchers said in background notes. The treatment involves placing electrodes on ...

Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality. HealthDay News — Attention-deficit ...

A recent study conducted by the FDA presented a good-news/huh?-news scenario about what drugs are given to children. As reported by Reuters Health, in the last decade, the number of drugs prescribed ...

The study included participants taking ADHD drug treatment (56.7%), and the researchers found this was associated with significantly reduced rates of suicidal behaviors, substance misuse, transport ...